Fred Hutchinson Cancer Research Center
Cell-Free DNA Analysis Predicts Preeclampsia Risk
Researchers used a new computational framework to predict preeclampsia risk from low-coverage whole-genome sequences generated on cell-free DNA found in maternal blood.
Clonal Expansion Limited in Stem Cell Transplant Recipients, Even After Long Time
Researchers used ultra-sensitive duplex sequencing to compare clonal hematopoiesis and myeloid cancer-related mutation patterns in transplant donors and recipients over time.
EpiCypher Licenses Chromatin Profiling Technology From Fred Hutchinson Cancer Center
The deal grants EpiCypher the license to three key areas of the CUT&Tag technology that will be integrated into the firm's product and service offerings.
Colorectal Cancer Studies Show Promise of Blood-, Stool-Based Screening
Research teams explored the performance of circulating cell-free DNA and stool DNA testing to find colorectal cancer in average-risk individuals.
AtlasXomics, EpiCypher Partner to Commercialize Spatial Epigenomics Assays
The companies will jointly develop spatial epigenomics assays using CUT&Tag reagents and antibodies from EpiCypher on AtlasXomics' DBiT-seq platform.